Welcome to our dedicated page for Theravance Biopharma news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Biopharma stock.
Theravance Biopharma, Inc. (NASDAQ: TBPH) is a leading biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. The company's mission is to pioneer a new generation of small-molecule drugs that better meet patient needs by maximizing efficacy while limiting systemic side effects.
Theravance Biopharma has a strong focus on inflammation and immunology and aims to deliver Medicines that Make a Difference® in people's lives. The company's research expertise has led to the development of the FDA-approved YUPELRI® (revefenacin) inhalation solution, the first once-daily, nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Theravance Biopharma co-promotes YUPELRI with Viatris Inc. under a profit and loss sharing arrangement.
Another promising product in Theravance Biopharma's pipeline is ampreloxetine, a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). This drug has the potential to be a first-in-class therapy, addressing a significant unmet medical need for MSA patients.
The company is also involved in strategic collaborations with other pharmaceutical companies to expand its reach and enhance its product pipeline. Their current projects and partnerships are aimed at furthering the development and commercialization of innovative therapies.
Financially, Theravance Biopharma has shown consistent performance, with significant growth in YUPELRI net sales and robust clinical trial activity. Recent achievements include positive results from a Phase III clinical trial of YUPELRI in China and ongoing enrollment in the Phase 3 CYPRESS study for ampreloxetine. These milestones underscore the company's commitment to delivering impactful therapies and driving shareholder value.
Theravance Biopharma continues to leverage its organ-selective drug development expertise to create value and improve patient outcomes. For more information, please visit www.theravance.com.
Theravance Biopharma (NASDAQ: TBPH) is set to announce its first quarter 2023 financial results on May 8, 2023, after market close. The announcement will be followed by a conference call at 5:00 pm ET, providing insights into the company’s business developments and performance metrics. Following the call, a replay will be accessible for 30 days until June 7, 2023. The company focuses on delivering innovative treatments, including its FDA-approved medication for COPD and a late-stage investigational drug for neurogenic orthostatic hypotension. The aim is to enhance shareholder value through its continuous development efforts.
Irenic Capital Management, a significant shareholder of Theravance Biopharma (NASDAQ: TBPH), expressed support for the recent appointment of Jim Kelly to the Board of Directors. Irenic believes Kelly will provide a key shareholder perspective that is essential for the boardroom. The firm commended Theravance for its efforts to enhance capital allocation, including expanding the capital return program and a proposal to declassify the Board. Irenic urged the Board to take further steps, such as reviewing strategic alternatives, accelerating the capital return program, and ensuring directors are elected on a one-year term. The emphasis remains on improving governance and value creation for shareholders.
Theravance Biopharma has appointed Jim Kelly, Managing Director at Weiss Asset Management and the Company's second largest shareholder, to its Board of Directors. This appointment is part of an ongoing board refreshment strategy, which has seen four new directors join since 2018. CEO Rick E Winningham emphasized Kelly's investment experience and understanding of the healthcare industry as valuable assets for the board. Kelly expressed commitment to leveraging his experience for the Company's success and shareholder returns. Weiss Asset Management manages approximately $3 billion in assets and has been a significant shareholder since 2021. Theravance focuses on developing impactful medicines, including the FDA-approved YUPELRI for COPD treatment and the investigational drug Ampreloxetine for neurogenic orthostatic hypotension.
Theravance Biopharma (NASDAQ: TBPH) will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 3:45 pm ET. The event will be accessible via webcast on Theravance.com in the Investors section.
Theravance Biopharma focuses on delivering innovative medicines, notably the FDA-approved YUPELRI (revefenacin) inhalation solution for chronic obstructive pulmonary disease (COPD). Additionally, the company is developing Ampreloxetine, a potential first-in-class norepinephrine reuptake inhibitor aimed at treating neurogenic orthostatic hypotension.
For further details about the conference and the company’s developments, visit www.theravance.com.
Theravance Biopharma (NASDAQ: TBPH) will participate in the 43rd Annual TD Cowen Health Care Conference on March 8, 2023, at 10:30 am ET. The event will include a Respiratory/Infections Corporate Panel Discussion.
The conference will be accessible via webcast on Theravance.com, where a replay will be available for 30 days. Theravance Biopharma is known for its FDA-approved YUPELRI® inhalation solution for COPD and is developing Ampreloxetine, targeting neurogenic orthostatic hypotension. The firm's commitment is towards improving patient lives and increasing shareholder value.
Theravance Biopharma (TBPH) has announced significant strategic moves, including increasing its capital return program from $250 million to $325 million. As of February 27, 2023, approximately $170 million remains in this program. The company reported $19.5 million in YUPELRI® sales for Q4 2022, a 27% year-over-year increase, marking its strongest quarter. Additionally, Theravance will discontinue research investments and reduce headcount by 17% to focus resources on the ampreloxetine Phase 3 study. The company reaffirmed its guidance for non-GAAP profitability in the second half of 2023.
Irenic Capital Management, a major shareholder of Theravance Biopharma (NASDAQ: TBPH), criticized the company's leadership and called for strategic changes. Since its separation in 2014, Theravance's total shareholder return has plummeted by -50%, reflecting a significant discount in its market value. Irenic proposed actions such as returning $300 million in excess cash to shareholders, reducing operational costs, and improving governance by appointing a shareholder representative. They estimate that adopting these measures could unlock nearly $21 per share in value, substantially higher than its current trading price of $9.87.
Theravance Biopharma (TBPH) will announce its fourth quarter and full-year 2022 financial results on February 27, 2023, after market close. A conference call and webcast are scheduled for 5:00 PM ET on the same day, allowing investors to gain insights into the company's performance. Interested parties can participate by pre-registering online. The company is known for its FDA-approved drug, YUPELRI, aimed at treating COPD and continues to focus on developing new therapies for unmet medical needs.
Theravance Biopharma (NASDAQ: TBPH) will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 8:00 am ET. The event can be accessed via a webcast on Theravance.com in the Investors section. A replay will be available for 30 days post-event. Theravance Biopharma is committed to delivering Medicines that Make a Difference and is known for its FDA-approved YUPELRI® inhalation solution for COPD. The company focuses on addressing significant unmet patient needs through its innovative pipeline.
Theravance Biopharma (TBPH) announced significant 2022 achievements and 2023 objectives. Key highlights include strategic advances in YUPELRI sales growth, with all-time high net sales reported in Q2 and Q3. The company initiated the Phase 3 CYPRESS study for ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) planned for Q1 2023, alongside a $250 million capital return program. With FDA discussions and a $1.1 billion royalty sale, Theravance aims for Non-GAAP profitability by 2H 2023, reinforcing its commitment to delivering impactful medicines.
FAQ
What is the current stock price of Theravance Biopharma (TBPH)?
What is the market cap of Theravance Biopharma (TBPH)?
What is Theravance Biopharma's primary focus?
What is YUPELRI?
What is ampreloxetine?
Who are Theravance Biopharma’s strategic partners?
What recent achievements has Theravance Biopharma made?
Where can I find more information about Theravance Biopharma’s products?
What is the purpose of the CYPRESS study?
How does Theravance Biopharma create shareholder value?
What is Theravance Biopharma’s mission?
How can I listen to Theravance Biopharma's conference calls?
